Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Patients with atopic dermatitis who had not received biologics prior to treatment with Opzelura were able to avoid biologics ...

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Larry Eichenfield, M.D., chief of pediatric and adolescent dermatology at Rady Children's Hospital, presented a session at ...

The ruxolitinib cream met its primary end point as a treatment for prurigo nodularis in one phase 3 trial but fell short in ...

Rebecca Vasquez, M.D., FAAD, said that while there is not enough data to support success stories yet, she has seen firsthand ...

Raising funding for research on social drivers of health may become an obstacle, given recent anti-DEI policies put into ...

In this analysis presented at the American Academy of Dermatology annual meeting, serious adverse events were low, unrelated ...

A break from treatment with Vtama won’t lead to worsening of patients’ atopic dermatitis, finds a new analysis of an ...

The advent of remibrtuinib, a Bruton's tyrosine kinase inhibitor, may encourage dermatologists to take care of chronic spontaenous urticaria patients, says a presenter at the 2025 meeting of the ...

The agreement was signed in a letter of intent March 3 to set the groundwork for whether government health programs in ...

Managed Healthcare Executive provides C-suite executives at health plans and provider organizations with news, analysis, ...